Form 4: Charles River Labs Director Acquires Shares

Director Martin MacKay of Charles River Laboratories International, Inc. reported the acquisition of 1,438 and 1,407 shares of common stock on May 8, 2026, at a price of $177.62 per share.

Summary

• Director Martin MacKay acquired a total of 2,845 shares of Charles River Laboratories International, Inc. common stock through two separate transactions on May 8, 2026.
• The shares were acquired at a price of $177.62 per share.
• Following these transactions, Mr. MacKay beneficially owns 15,730 shares directly and an additional 17,137 shares directly.
• The first acquisition of 1,438 shares was designated as a purchase at $177.62.
• The second acquisition of 1,407 shares was also at $177.62 and is described as a grant in lieu of director service fees for the term commencing May 5, 2026.
• Both grants of restricted stock units vest on the earlier of May 8, 2027, or the business day prior to the Company's next annual meeting of shareholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a director's acquisition of shares, which can be interpreted as a sign of confidence, but it does not involve significant new capital or strategic shifts.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 2,845 shares by a director indicates continued commitment to the company.
• The grant of restricted stock units for director service fees aligns director compensation with long-term company performance, with vesting tied to future events.

Future Outlook

The restricted stock units acquired by Director MacKay are subject to vesting conditions tied to future dates, specifically May 8, 2027, or the business day prior to the Company's next annual meeting of shareholders, indicating a forward-looking compensation structure.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as they can provide insights into management's perception of the company's valuation and future performance within the contract research organization (CRO) and life sciences industry.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares positively, potentially indicating confidence in the company's future performance.
• Employees may see this as a sign of stability and commitment from leadership.
• Creditors and suppliers are unlikely to be directly impacted by this specific transaction.

Next Steps

• Vesting of restricted stock units on May 8, 2027, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Director Acquisition, Restricted Stock Units, Beneficial Ownership, Securities Exchange Act